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 
Abstract—Peroxisome Proliferator Activated Receptors are 
lipid-sensors and regulate energy metabolism. The agonists of 
PPARs are of interest to the pharmaceutical industry since they 
regulate the expression of genes associated with diseases like 
cancer, diabetes, atherosclerosis and obesity. Synthetic agonists 
are more likely to cause side effects. Hence eight naturally 
occuring lipid ligands (tocotrienol α, β, γ and δ, DHA, EPA, 
2-Arachidonyl Glycerol and Anandamide) were tested for their 
ability to act as the agonists of PPARs. DHA and EPA were 
identified as the dual agonists of PPAR α and γ. DHA and EPA 
have beneficial health effects in the treatment of cancer, obesity 
and inflammatory diseases. Two different docking methods 
Autodock and Glide were performed to compare their 
suitability for PPARs. Interestingly in both the docking 
programs the ligands have occupied the same binding pocket 
confirming the selection of active site. Autodock yielded better 
results than Glide for PPAR α and γ whereas the performance 
of Glide was better in case of PPAR δ. 
 
Index Terms—Agonists of PPARs, autodock, glide, omega 3 
fatty acids. 
 
I. INTRODUCTION 
Peroxisome Proliferator Activated Receptors (PPARs) are 
members of the nuclear receptor family. They exist in three is 
forms: PPAR α, PPAR β/δ and PPAR γ. The pharmaceutical 
industry is paying more attention to the research of PPAR 
agonists, since PPARs regulate the gene expression of 
different diseases like cancer, diabetes, atherosclerosis and 
obesity [1]. PPARs regulate energy metabolism by each 
carrying out a unique function and serve as therapeutic 
targets to treat obesity and homeostasis [2]. PPAR α and γ are 
expressed in liver and adipose tissue, respectively. PPAR δ is 
expressed throughout the body and low levels in liver. PPAR 
γ acts as a molecular target for the anti-diabetic drugs 
thiazolidinediones (TZDs). Recent research suggests that 
PPAR γ has a therapeutic potential to treat inflammatory 
diseases and certain cancers [3]. PPAR α is the molecular 
target for lipid-lowering fibrate drugs. The metabolic 
regulatory role of PPAR δ is recently recognized and clinical 
trials for PPAR δ agonists are underway [2]. 
PPARs are lipid-sensors that can be activated by both 
dietary fatty acids and their metabolic derivatives in the body 
[2].   
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The long and medium chain unsaturated fatty acids are the 
most abundant ligands of PPARs [4]. Considering these facts, 
three classes of natural lipid ligands are selected to test their 
ability as potential agonists of PPARs. Four isomers of 
tocotrienols: tocotrienol α, β, γ and δ belong to class one of 
lipids. Omega 3 Fatty acids (Docosahexaenoic acid, DHA 
and Eicosapentanoic acid, EPA) are considered under class 
two of lipid ligands. Endocannabinoids (2-Arachidonyl 
glycerol and Anandamide) are the third class of lipid ligands. 
The above ligands are selected since fatty acids and 
eicosanoids are natural agonists of PPARs [5]. Moreover the 
synthetic ligands cause more side effects than the natural 
ligands [6]. 
All the eight lipid ligands used in the current study are 
chemically active and medicinally significant. Tocotrienols 
were demonstrated to have positive health effects on bone 
health, brain health, blood sugar metabolism and cancer [7]. 
Animal studies suggest that omega 3 fatty acids exert 
protective effects against breast, colon and prostate cancers. 
In patients with colorectal cancer DHA and EPA decrease 
cell proliferation and maintain the balance between colonic 
cell proliferation and apoptosis [8]. Endocannabinoids are 
used in the treatment of obesity and as an aid in the cessation 
of smoking [9]. Endocannabinoids are capable of reducing 
inflammation, cell proliferation and cell survival and hence 
can be used in cancer treatment [10]. 
In the current study the binding mechanism of PPARs with 
the above mentioned eight lipid ligands was studied through 
molecular docking. Two different docking tools, AutoDock 
(http://autodock.scripps.edu) and Glide [11], were used to 
identify which docking method works better with the target 
proteins and lipids. The binding of PPARs with the above 
mentioned eight lipid ligands was not performed before 
either insilico or invitro.  
This paper is organized as follows. Section II describes the 
literature review carried as part of the current research. 
Methods performed were mentioned in Section III. The 
findings from the current research work are included in 
Section IV. Section V and Section VI are about the 
conclusion and future work. 
 
II. LITERATURE REVIEW 
The limitations of currently used PPAR based drugs have 
laid a foundation for the current docking study of finding the 
new agonists that activate PPARs. Anti-diabetic and 
hypolidemic drugs are PPAR-based. However their use is 
contraindicated in patients with high lipid levels [12]. For 
example widely used TZDs result in some side effects like 
obesity and developing the risk of cardiovascular disease 
[13]. PPAR α-based lipid-lowering fibrate drugs are limited 
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in their efficacy due to restricted selectivity [14]. 
Therefore there is a need to find potential agonists of 
PPAR γ and α that cause few or no side effects. Moreover the 
dual agonists of PPAR α and γ are of interest to the 
pharmaceutical industry. Though a similar docking study was 
conducted before for the binding affinities of PPARs, the 
study was limited to DHA [12]. 
The current docking study is also useful in finding the 
potential molecular target of PPAR δ. Because of number of 
docking tools available today, it is always a challenge to 
select the suitable technique for a target protein. Hence two 
widely used docking techniques AutoDock and Glide were 
compared to find out the best suitable docking tool for 
PPARs. The current molecular docking study is novel as it 
proposes the dual agonists of PPAR α and γ and agonists of 
PPAR δ. Furthermore, the present research is unique as the 
suitable docking tool for PPARs was identified. 
III. METHODS
PPAR α, β and γ are tested for their binding affinities with 
eight lipid ligands (α, β, γ and δ tocotrienols, DHA, EPA, 
2AG and Anandamide) using two different docking methods- 
AutoDock and Glide.  
A. Ligand Preparation 
The three dimensional structures of all the eight ligands 
were downloaded from Pubchem website 
(http://pubchem.ncbi.nlm.nih.gov/) as the website has a huge 
collection of ligand structures. The ligand structures are 
minimized with Chimera (http://www.cgl.ucsf.edu/chimera) 
to perform AutoDock. Hydrogens are added using AutoDock 
tools. The LigPrep module of Maestro v9.2 in the 
Schrodinger suite of tools [15] is used for the ligand 
preparation to perform Glide docking.  
B. Protein Preparation and Receptor Grid Generation 
The three dimensional structures of PPAR α, β and γ were 
downloaded from Protein Data Bank website (www.pdb.org). 
PDB codes 3FEI, 3GZ9 and 3FEJ were used for the crystal 
structures of PPAR α, β and γ respectively. Refining the 
crystal structures by removing crystal ligands and water 
molecules is performed using Chimera prior to using 
AutoDock. The amino acids Cys 275, Cys 276, Met 330 and 
Met 355 were considered as the active site for the protein 
PPAR α [16]. For PPAR δ the combination of amino acids 
His 323, His 449, Tyr 473, Cys 285 and Thr 288 is the active 
site [17]. Met 364, Cys 285, Met 348 and Gly 284 are the 
active site amino acids for PPAR γ [16]. The receptor grids 
are generated for the active site amino acids. 
To perform Glide docking the protein structures were 
prepared using the Protein Preparation Wizard of Maestro. 
The crystal ligand CTM is used for the receptor grid 
generation of both PPAR α and γ, whereas for PPAR δ the 
crystal ligand is D32. Except for the bridging water 
molecules rest of them were deleted during the minimization 
of proteins. 
C. Validation of Docking Studies 
Redocking is performed as a validation method for all 
docked protein-ligand complexes. The three dimensional 
structures of crystal ligands were obtained by removing the 
crystal ligand from protein crystallographic complexes. The 
crystal ligands are then redocked with the three PPAR 
proteins using AutoDock and Glide. Root Mean Square 
Deviation (RMSD) values between crystal ligand and 
predicted confirmations were calculated using Pymol 
software (http://www.pymol.org/).
D. Docking Studies 
Docking is performed by using two different methods: 
AutoDock and Glide. PPARα, β and γ were docked with the 
above mentioned eight lipid ligands. Genetic algorithm GA 
with 10 iterative runs and Lamarckian genetic algorithm were 
selected to perform AutoDock. The results of AutoDock 
were analyzed using VMD software 
(http://www.ks.uiuc.edu/Research/vmd/). Extra Precision 
(XP) mode of Glide docking is performed with the receptor 
grid files and prepared ligand structures. Ligplot software 
(http://www.ebi.ac.uk/thornton-srv/software/LIGPLOT) is 
used to study the bonded interactions of PPARs with lipid 
ligands. 
IV. RESULTS AND DISCUSSION
A. Redocking as a Docking Validation Method 
Redocking is the most significant validation method to 
evaluate the accuracy of the docking procedure [18]. 
Redocking determines how closely the lowest binding energy 
pose resembles the experimental binding mode determined 
by X-ray crystallography. In the current study, AutoDock and 
Glide were validated by removing the crystal ligand (CTM 
for PPAR α and γ and D32 for PPAR δ) from the binding site 
and redocking it to the binding site of PPAR α (PDB code: 
3FEI), PPAR γ (PDB code: 3FEJ) and PPAR δ (PDB code: 
3GZ9). The alignment of PPAR α, PPAR β and PPAR γ with 
crystal ligand were depicted in Fig. 1, Fig. 2 and Fig. 3 
respectively where the redocked ligand is shown in red color. 
 
 
Fig. 1. Redocking of ppar alpha with crystal ligand. 
 
 
Fig. 2. Redocking of ppar delta with crystal ligand. 
  
 
 
 
Fig. 3. Redocking of PPAR gamma with crystal ligand. 
 
The crystal ligand is removed from the binding site and 
superimposed with X-ray crystal structures of PPARs and 
RMSD were calculated. RMSD between the predicted 
confirmation and the observed binding mode for all three 
isoforms of PPARs is less than 2A0 and is similar in both 
AutoDock and Glide (Table I). RMSD values between 
crystal and predicted confirmation is an indicator of whether 
or not correct docking was obtained from a particular 
docking method [19]. RMSD less than 2A0 is the cut-off of 
correct docking, perhaps because the resolution in an X-ray 
crystallography is often about 2A0  and higher precision than 
the resolution of crystal structure analysis is not meaningful 
[18]. Therefore AutoDock and Glide docking performed in 
the current study were considered to be successful as the 
RMSD between crystal and predicted confirmation is less 
than 2A0 (Table I). 
 
TABLE I: RMSD VALUES OF CRYSTAL LIGAND  
Serial  
Number 
Protein 
Crystal     
 Ligand 
RMSD 
AutoDock 
RMSD 
Glide 
1. PPAR α CTM 0.160 0.169 
2. PPAR δ D32 0.203 0.123 
3. PPAR γ CTM 0.165 0.162 
 
B. Docking Analysis 
The research on agonists of PPARs is significant as PPARs 
play key roles in the regulation of energy homoeostasis and 
inflammation [20]. The agonists of PPARs are currently used 
therapeutically. The dual agonists of PPAR α and γ are used 
in the treatment of diabetes and dyslipidemia and hence are of 
high importance. The anti-diabetic drugs thiazolidinediones 
(TZDs) use PPAR γ as a molecular target [13]. However 
TZDs cause side effects like obesity and cardiovascular 
diseases [13]. A potential therapeutic target of PPAR δ is 
under investigation [20]. Considering the medicinal 
importance of PPARs in the treatment of different diseases 
like diabetes, atherosclerosis and cancer they are docked with 
eight lipid ligands to test their potentiality as PPAR agonists. 
Moreover, the lipid ligands used in the current study are 
also medicinally significant. For example, tocotrienols are 
chemically active and are used in the treatment of breast 
cancer [7]. Omega 3 fatty acids (DHA and EPA) play an 
important role in the pathophysiology and treatment of 
bipolar disorder [21]. Endocannabinoids can reduce 
inflammation, cell proliferation and cell survival and hence 
can be used in the treatment of cancer [10]. These facts imply 
that the current docking experiment is significant as a way of 
designing PPAR-based drugs. 
The binding energies of PPAR α, β and γ, achieved 
through using AutoDock and Glide were mentioned in Table 
II. Out of all the eight ligands tested in the current docking 
study DHA has expressed strong binding with both PPAR α 
and γ. Therefore DHA can be considered as a dual agonist of 
PPAR α and γ. Interestingly, DHA has shown strong binding 
affinity than the crystal ligand CTM. CTM was considered as 
crystal ligand as it was identified as a potential dual agonist 
of PPAR α and γ in previous studies. In an experiment PPARs 
were tested for their binding affinity with 26 ligands where 
CTM was identified as strong affinity dual agonist of PPAR α 
and γ [16]. Apart from CTM, DHA was also proved to have 
strong affinity with the TZDs of rosiglitazone [12] and 
pioglitazone [22]. The current in silico experiment shows that 
DHA has strong affinity with PPAR α and γ and so can be 
considered as potential natural dual agonist of PPAR α and γ. 
Comparatively, omega 3 fatty acids (DHA and EPA) have 
shown strong binding with PPAR α and γ (Table II). It was 
also proved in another experiment that DHA activates PPAR 
α and γ genes [22]. Furthermore, all four isoforms of 
tocotrienols can be considered as dual agonists of PPAR α 
and γ since they exhibited strong affinity than the crystal 
ligand CTM (Table II).  
 
TABLE II: BINDING ENERGIES OF PPARS IN AUTODOCK AND GLIDE 
Protein 
 
 
Ligand 
AutoDock-Lowest 
binding energy 
(Kcal/m) 
Glide 
Score(K
cal/m) 
PPAR α DHA -11.5 -10.2 
PPAR α EPA -10.1 -9.3 
PPAR α 2AG -7.69 -8.0 
PPAR α Anandamide -6.57 -5.6 
PPAR α α tocotrienol -9.87 -7.1 
PPAR α β tocotrienol -9.98 -7.5 
PPAR α γ tocotrienol -8.44 -7.3 
PPAR α δ tocotrienol -9.53 -7.5 
PPAR α CTM -7.72 -7.5 
PPAR β DHA -11.40 -15.8 
PPAR β EPA -10.93 -14.8 
PPAR β 2AG -9.22 -10.8 
PPAR β Anandamide -8.67 -9.7 
PPAR β α tocotrienol -9.20 -9.7 
PPAR β β tocotrienol -9.97 -9.3 
PPAR β γ tocotrienol -9.09 -9.8 
PPAR β δ tocotrienol -9.31 -7.7 
PPAR β D32-Cryslig -10.2 -11.7 
PPAR γ DHA -11.71 -10.3 
PPAR γ EPA -10.22 -9.4 
PPAR γ 2AG -7.74 -7.7 
PPAR γ Anandamide -6.29 -5.2 
PPAR γ α tocotrienol -8.93 -8.2 
PPAR γ β tocotrienol -8.95 -8.4 
PPAR γ γ tocotrienol -9.66 -8.5 
PPAR γ δ tocotrienol -9.68 -8.5 
PPAR γ CTM -8.0 -8.1 
 
Endocannabinoids have shown poor affinity with PPAR α 
and γ compared to omega 3 fatty acids and tocotrienols. 
PPAR α and γ are similar in their binding with the lipid 
ligands used in the current docking study. PPAR δ also 
showed strong binding with omega 3 fatty acids than with the 
crystal ligand D32. However, unlike PPAR α and γ, PPAR δ   
has poor affinity with tocotrienols than with the crystal ligand 
D32. Similar to PPAR α and γ, PPAR δ expressed strong 
affinity with the crystal ligand D32 than with 
endocannabinoids. 
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C. Binding Mode of Lowest Binding Energy Poses 
 
 
 
Fig. 4. Bonded interactions of PPAR alpha with DHA. 
 
 
Fig. 5. Bonded interactions of PPAR delta with DHA. 
 
 
Fig. 6. Bonded Interactions of PPAR gamma with DHA. 
TABLE III: INTERACTING AMINO ACIDS OF PPARS IN AUTODOCK AND 
GLIDE 
Protein Ligand 
Interacting 
Amino acids within 
4A0 distance in 
Auto Dock 
Interacting 
Amino acids 
within 4A0 
distance in Glide 
PPAR 
α 
DHA 
Met 330,Met355  
Cys 275,Cys 276 
Thr 279,Ser 280 
Met 330,Met355  
Cys 275,Cys 276  
Thr 279,Ser 280 
AR α EPA 
Met 355,Ser 280 
Met 330,Thr 279 
Cys 276,Tyr 334 
Met 355,Ser 280 
Met 330,Thr 279  
Cys 276,Tyr 314 
PPAR 
α 
2AG 
Tyr334,Ala 333 
Met 330,Cys 275 
Asn 219,His 440 
Tyr 334,Ala 333   
Met 330,Cys 275  
Asn 219,His 440 
PPAR 
α 
Anandamide 
Cys 276,Thr 279  
Tyr 334,Val 332  
Met 330,Cys 375 
Cys 276,Thr 279  
Tyr 334,Val 332  
Met 330,Tyr 464 
PPAR 
α 
α tocotrienol 
Met 330,Met 355 Cys 
275,Cys 276  
Ala 333,Thr 279 
Met 330,Met 355  
Cys 275,Cys 276  
Ala 333,Val 324 
PPAR 
α 
β tocotrienol 
Met 330,Met 355 Cys 
275,Cys 276 
Val 332,Val 324 
Met 330,Met 355  
Cys 275,Cys 276 
Val 332,Ser 380 
PPAR 
α 
γ tocotrienol 
Met 330,Met 355 Cys 
276,Ser 280 
Thr 279,Val 332 
Met 330,Met 355 
Cys 276, Ser 280  
Thr 279,Val 332 
PPAR 
α 
δ tocotrienol 
Met 330,Met 355 Cys 
275, Cys 276 
Val 332, Met 320 
Met 330,Met 355  
Cys 275,Cys 276  
Val 332, Met 320 
PPAR β DHA 
His 323, His 449 
Tyr 473, Ile 363 
Leu 330, Val 341 
His 323,His 449  
Tyr 473,Ile 363 
 Leu 339,Ala 342 
PPAR β EPA 
His 323,His 449  
Tyr 473,Thr 288 
Phe 282, Ile 364 
His 323,His 449  
Tyr 473,Thr 288 
Phe 282, Ile 363 
PPAR β 2AG 
Thr 288,Met 453 
Phe 282,Cys 285 
His 449,Leu 330 
Thr  288,Met 453 
Phe 282,Cys 285 
His 449, Leu 330 
PPAR β Anandamide 
His 449,Thr 288 
Ile 364,Leu 330 
Ala 342,Cys 285 
His 449, Thr 288 
Ile 364,Leu 330 
Met 453,Cys 285 
PPAR β α tocotrienol 
His 449, Ile 363, 
Ala 342, Cys 285 
Ile 363, Arg 284 
His 449, Ile 363 
Cys 285, Thr 288 
His 323, Tyr 473 
PPAR β β tocotrienol 
Cys 285, Tyr 473 
His 449, Leu 330 
Phe 282, Met 453 
Cys 285, Tyr 473 
Met 453, Ile 363 
His 323, His 449 
PPAR β δ tocotrienol 
His 449, Tyr 473 
Met 453, Ile 364 
Ala 342, Cys 285 
His 449, Tyr 473  
Met 453, Ile 363 
Cys 285, His 323 
PPAR γ DHA 
Cys 285, Met 364 
Phe 282, Met 355 
Met 330, Arg 288 
Met 355, Met 330 
Ser 280, Cys 285 
Met 364 ,Ala 333 
PPAR γ EPA 
Cys 285, Met 364 
Ser 289, Met 330 
Tyr 327, Arg 288 
Cys 285,Met 364 
Tyr 473,Met 330 
Tyr 327,Met 348 
PPAR γ 2AG 
Cys 285, Gly 286 Met 
364, Leu 330 
His 449, Arg 288 
Cys 285,Gly 286  
Met 364,Leu 330  
His 449,Arg 288 
PPAR γ Anandamide 
Cys 285, Leu 330 
Met 364, Tyr 473 
His 449, Ser289 
Cys 285,Leu 330 
Met 364,Tyr 473 
His 449, Ser289 
PPAR γ α tocotrienol 
Cys 285, Met 348 Met 
364, Gly 284 
Arg 288, Leu 330 
Cys 285,Met 348  
Met 364,Gly 284 
Arg 288,Leu 330 
PPAR γ β tocotrienol 
Cys 285, Met 348 Met 
364, Gly 284 
Arg 288, His 449 
Cys 285,Met 348 
 Met 364,Gly 284 
Arg 280,His 449 
PPAR γ γ tocotrienol 
Cys 285, Met 348 Met 
364, Gly 284, 
Phe 282, Tyr 327 
Cys 285,Met 348 
Met 364,Gly 284, 
Phe 282,Tyr 373 
PPAR γ δ tocotrienol 
Cys 285, Met 348 Met 
364, Gly 284 
His 323, Tyr 473 
Cys 285,Met 348  
Met 364,Gly 284 
His 449,Tyr 473 
 
PPAR α has formed hydrophobic interactions with the 
active site amino acids Cys 275, Cys 276, Met 330 and Met 
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Interestingly in both AutoDock and Glide docking tools
the ligands have occupied the same binding pocket indicating 
the accuracy of the active site selected to generate the 
receptor grid. The hydrogen bonded and hydrophobic 
interactions of DHA with PPAR α, PPAR β and PPAR γ were 
represented in Fig. 4, Fig. 5 and Fig. 6 respectively where 
hydrogen bonds and bond distances are represented in green 
colors and hydrophobic amino acids in purple color. 
  
 
 
355 (Fig. 4). Oxygen (O) 1 located on carbon (C) 21 of DHA 
has formed two hydrogen bonds with His 440 and Tyr 364 
with bond distances 3.06A0 and 2.62A0 respectively. Ser 280 
and Tyr 314 have formed hydrogen bonds with O2 of C21 on 
DHA with bond distances 2.78A0 and 2.51A0 as shown in Fig. 
4. 
In the case of PPAR δ, the active site amino acids His 323, 
His 449 and Tyr 473 have formed hydrogen bonds with the 
ligand (Fig. 5). His 323 and Tyr 473 have formed two 
hydrogen bonds with O1 located on C21of DHA with bond 
distances 2.67A0 and 2.72A0 respectively (Fig. 5). O2 on 
C21 of DHA formed a hydrogen bond with His 323 in 
distance of 2.72A0. Cys 285, Thr 289, Ile 363, Thr 279 have 
formed hydrophobic interactions with the ligand. The active 
site amino acids Cys 285, Met 348, met 364 and Gly 284 of 
PPAR γ have formed hydrophobic interactions with the 
ligand. His 449 and Tyr 473 of PPAR γ have formed two 
hydrogen bonds with O1 located on C21 of DHA with a bond 
distance of 3.08A0 and 2.76A0 as shown in Fig. 6. Two more 
hydrogen bonds were observed with O2 on C21 of DHA with 
bond a distance of 2.93 from His 323 and 2.70 from Ser 289 
(Fig. 6). 
To conclude, omega 3 fatty acids are potential agonists for 
all three isoforms of PPARs. In comparison, tocotrienols are 
the dual agonists of PPAR α and γ. 
D. Comparison of AutoDock and Glide 
 
 
Fig. 7. Comparision of binding energies of PPAR alpha in AutoDock and 
glide. 
 
AutoDock and Glide have generated similar binding 
energies for all the three isoforms of PPARs with all the eight 
lipid ligands docked in the current study (Table I). In order to 
compare the similarity between both AutoDock and Glide, 
the interacting amino acids within 4A0 distance from the 
ligand were shown in Table III.  
The common interacting amino acids of both the docking 
methods were represented in bold.  
The active site is confirmed for PPARs since the ligands 
occupied the same binding site in both AutoDock and Glide 
programs. Though AutoDock and Glide uses different 
scoring functions, they resulted in generating the similar 
binding energies. AutoDock uses empirical scoring function 
and Glide uses XP scoring function. Apart from the slight 
difference in the binding energies generated from AutoDock 
and Glide docking tools, the interaction of protein with 
ligand is similar in both the methods. Using two different 
methods of docking and resulting in similar interaction of 
target proteins with ligand indicates the accuracy of the 
current insilico experiment. 
 
 
Fig. 8. Comparision of binding energies of PPAR delta in AutoDock and 
glide. 
 
 
Fig. 9. Comparision of binding energies of PPAR gamma in AutoDock and 
glide. 
 
 
Fig. 10. Comparision of binding energies of PPARs in AutoDock and glide. 
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AutoDock worked well for the proteins PPAR α and γ
whereas Glide yielded better results for PPAR δ. To compare 
the efficiency of both AutoDock and Glide the bar graphs 
were drawn with the help of binding energies obtained from 
both the docking methods. AutoDock is efficient for both 
PPAR α and γ while Glide is an efficient tool for PPAR δ (Fig.
10). Individual efficiency of AutoDock and Glide for the 
interaction of eight lipid ligands with PPAR α, β and γ is 
shown in Fig. 7, Fig. 8 and Fig. 9 respectively.
  
 
 
V. CONCLUSIONS 
Redocking is performed as a validation method of 
AutoDock and Glide. Omega 3 fatty acids were observed as 
the dual agonists of PPAR α and γ. Tocotrienols and omega 3 
fatty acids have shown strong binding affinity with PPAR α 
and γ than with the crystal ligand CTM. PPAR δ has shown 
strong binding affinity with omega 3 fatty acids compared to 
the other two classes of lipid ligands. AutoDock was 
identified as a suitable docking program for PPAR α and γ 
whereas for PPAR δ Glide is the suitable docking program. 
In both AutoDock and Glide the ligands have occupied the 
same binding pocket generating the similar docking poses.  
 
VI. FUTURE WORK 
Omega 3 fatty acids and tocotrienols can further be tested 
invitro for their ability to act as the dual agonists of PPAR α 
and γ. The dual agonists of PPAR α and γ are significant in 
anti-diabetic and anti-cancer therapy. For the research of 
PPAR δ agonists omega 3 fatty acids can be considered and 
further tested. 
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